Circulating Tumor DNA, or ctDNA, is fragments of DNA shed from cancer cells, found in the bloodstream and collected using a blood draw. Blood samples are analyzed to detect and quantify ctDNA, revealing specific alterations (abnormal changes) in the DNA. ctDNA can serve as a biomarker for diagnosing certain cancers, planning treatment, monitoring treatment effectiveness, and checking for cancer recurrence.

Read more about ctDNA and its potential use as a biomarker for tracking treatment response and understanding associations with outcomes in drug development on our ctMoniTR Project page.